Important New Trial With Oral FERACCRU(R) Shows Comparable Efficacy to IV Iron (Ferric Carboxymaltose), Offering a Real Alternative to Hospital Administration for Many Patients[4]

FERACCRU® (Ferric Maltol) met primary endpoint against Ferinject® (IV Ferric Carboxymaltose (FCM)) and shows clear benefits to Iron Deficiency Anaemia (IDA) patients with inactive Inflammatory Bowel Disease (IBD)4 FERACCRU® delivered a haemo... Biopharmaceuticals Norgine, Shield Therapeutics, FERACCRU, Ferric Maltol, Iron Deficiency Anaemia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news